Division of Chest Surgery, Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Surg Today. 2020 Dec;50(12):1578-1584. doi: 10.1007/s00595-020-01988-7. Epub 2020 Mar 19.
In 1970, neuroendocrine tumors of the lung were classified into three categories: typical carcinoid (TC), atypical carcinoid (AC), and small cell lung carcinoma (SCLC). The third edition of the World Health Organization (WHO) classification in 1999 defined large cell neuroendocrine carcinoma (LCNEC) as a variant of large cell carcinomas, whereas the fourth edition of the WHO classification redefined LCNEC as a neuroendocrine tumor. Currently, neuroendocrine tumors of the lung are classified into four main categories: TC, AC, LCNEC, and SCLC. Although the treatments for TC, AC, and SCLC have not changed remarkably, the treatment strategy for LCNEC is not yet established because of its reclassification from a variant of "large cell carcinoma" to a new category of "neuroendocrine tumor". In this review article, we discuss the pathological findings, biological behavior, and treatment of neuroendocrine tumors of the lung.
1970 年，肺神经内分泌肿瘤被分为三类：典型类癌（TC）、非典型类癌（AC）和小细胞肺癌（SCLC）。1999 年世界卫生组织（WHO）第三版分类将大细胞神经内分泌癌（LCNEC）定义为大细胞癌的一种变体，而第四版 WHO 分类将 LCNEC 重新定义为神经内分泌肿瘤。目前，肺神经内分泌肿瘤分为四大类：TC、AC、LCNEC 和 SCLC。尽管 TC、AC 和 SCLC 的治疗方法没有显著改变，但由于 LCNEC 从“大细胞癌”的变体重新分类为“神经内分泌肿瘤”的新类别，其治疗策略尚未确定。在这篇综述文章中，我们讨论了肺神经内分泌肿瘤的病理发现、生物学行为和治疗。
